title: Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.
abstract: BACKGROUND
  The renin-angiotensin-aldosterone system (RAAS) has recently been considered as a possible link between bone and vascular disease. The present study was designed to determine the effect of the angiotensin II receptor blocker candesartan on circulating osteoprotegerin (OPG) in hypertensive patients with multiple cardiovascular risk factors.
  
  
  METHODS
  A total of 69 hypertensive patients were randomized to two groups: Group 1 included patients treated with oral candesartan in doses of 16 mg to 32 mg per day in addition to routine standard of care (routine care + ARB), and Group 2 included patients who received routine standard of care other than ARBs or ACEIs, with no change to their treatment (routine care). Patients were evaluated for lipid profile, HbA1C, insulin, C-peptide, CRP, aldosterone, renin, homeostasis model assessment-insulin resistance (HOMA-IR) and OPG.
  
  
  RESULTS
  Baseline OPG levels did not differ significantly by treatment group. Post-treatment serum OPG levels were marginally lower in Group1 compared with Group 2; however, this decrease did not reach statistical significance (p = 0.077).
  
  
  CONCLUSIONS
  In the present study, treatment with the ARB candesartan had no significant effect on circulating OPG levels in hypertensive patients with multiple cardiovascular risk factors. To the best of our knowledge, the present study is the first to estimate an effect of candesartan on bone remodeling marker such as OPG.
authors.affiliation: Department of Arthroscopy and Sport Medicine, Wolfson Medical Center, Israel.
authors.forename: H
authors.initials: H
authors.lastname: Oz
authors.affiliation: Department of Medicine, Wolfson Medical Center, Israel Department of Endocrinology, Wolfson Medical Center, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Gavish
authors.affiliation: Department of Medicine, Wolfson Medical Center, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Hass
authors.affiliation: Department of Endocrinology, Wolfson Medical Center, Israel Sackler Faculty of Medicine, Tel Aviv University, Israel marinas@wolfson.health.gov.il.
authors.forename: M
authors.initials: M
authors.lastname: Shargorodsky
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D001842:Bone and Bones / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D053244:Osteoprotegerin; C506030:TNFRSF11B protein, human; D013777:Tetrazoles; C081643:candesartan
keywords: Angiotensin II receptor blocker; osteoprotegerin; renin-angiotensin-aldosterone system